miltefosine has been researched along with Trypanosomiasis, African in 8 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
Trypanosomiasis, African: A disease endemic among people and animals in Central Africa. It is caused by various species of trypanosomes, particularly T. gambiense and T. rhodesiense. Its second host is the TSETSE FLY. Involvement of the central nervous system produces African sleeping sickness. Nagana is a rapidly fatal trypanosomiasis of horses and other animals.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This work describes the optimization of the pharmacokinetic properties of a previously published family of triazine lead compounds." | 1.48 | Optimization of the pharmacokinetic properties of potent anti-trypanosomal triazine derivatives. ( Augustyns, K; Baán, A; Caljon, G; Kiekens, F; Maes, L; Matheeussen, A; Salado, IG; Van der Veken, P; Verdeyen, T, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferrins, L | 1 |
| Rahmani, R | 1 |
| Sykes, ML | 1 |
| Jones, AJ | 1 |
| Avery, VM | 1 |
| Teston, E | 1 |
| Almohaywi, B | 1 |
| Yin, J | 1 |
| Smith, J | 1 |
| Hyland, C | 1 |
| White, KL | 1 |
| Ryan, E | 1 |
| Campbell, M | 1 |
| Charman, SA | 1 |
| Kaiser, M | 3 |
| Baell, JB | 1 |
| Papadopoulou, MV | 1 |
| Bloomer, WD | 1 |
| Rosenzweig, HS | 1 |
| Wilkinson, SR | 1 |
| Szular, J | 1 |
| Jagu, E | 1 |
| Pomel, S | 1 |
| Diez-Martinez, A | 1 |
| Ramiandrasoa, F | 1 |
| Krauth-Siegel, RL | 1 |
| Pethe, S | 1 |
| Blonski, C | 1 |
| Labruère, R | 1 |
| Loiseau, PM | 2 |
| Salado, IG | 1 |
| Baán, A | 1 |
| Verdeyen, T | 1 |
| Matheeussen, A | 1 |
| Caljon, G | 1 |
| Van der Veken, P | 1 |
| Kiekens, F | 1 |
| Maes, L | 1 |
| Augustyns, K | 1 |
| Saccoliti, F | 1 |
| Madia, VN | 1 |
| Tudino, V | 1 |
| De Leo, A | 1 |
| Pescatori, L | 1 |
| Messore, A | 1 |
| De Vita, D | 1 |
| Scipione, L | 1 |
| Brun, R | 2 |
| Mäser, P | 1 |
| Calvet, CM | 1 |
| Jennings, GK | 1 |
| Podust, LM | 1 |
| Costi, R | 1 |
| Di Santo, R | 1 |
| Papagiannaros, A | 1 |
| Bories, C | 1 |
| Demetzos, C | 1 |
| Croft, SL | 1 |
| Snowdon, D | 1 |
| Yardley, V | 1 |
| Konstantinov, SM | 1 |
| Kaminsky, R | 1 |
| Berger, MR | 1 |
| Zillmann, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705] | Phase 3 | 437 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 85 |
| Glucantime® | 103 |
| Thermotherapy | 86 |
At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 34 |
| Glucantime® | 14 |
| Thermotherapy | 42 |
Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment
| Intervention | Participants (Number) |
|---|---|
| Miltefosine | 3 |
| Glucantime® | 4 |
| Thermotherapy | 6 |
8 other studies available for miltefosine and Trypanosomiasis, African
| Article | Year |
|---|---|
3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis.
Topics: Anilides; Animals; Humans; Mice; Myoblasts, Skeletal; Rats; Species Specificity; Structure-Activity | 2013 |
Nitrotriazole-based acetamides and propanamides with broad spectrum antitrypanosomal activity.
Topics: Acetamides; Animals; Mice; Nitroreductases; Structure-Activity Relationship; Triazoles; Trypanocidal | 2016 |
Synthesis and in vitro antikinetoplastid activity of polyamine-hydroxybenzotriazole conjugates.
Topics: Animals; Antiprotozoal Agents; Humans; Leishmania donovani; Leishmaniasis, Visceral; NADH, NADPH Oxi | 2017 |
Optimization of the pharmacokinetic properties of potent anti-trypanosomal triazine derivatives.
Topics: Animals; Disease Models, Animal; Humans; Mice; Structure-Activity Relationship; Triazines; Tropolone | 2018 |
Biological evaluation and structure-activity relationships of imidazole-based compounds as antiprotozoal agents.
Topics: Animals; Antiprotozoal Agents; Cell Line; Chagas Disease; Female; Humans; Imidazoles; Inhibitory Con | 2018 |
Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations.
Topics: Amines; Animals; Chemistry, Pharmaceutical; Disease Models, Animal; Dose-Response Relationship, Drug | 2005 |
The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei.
Topics: Animals; Antineoplastic Agents; Chagas Disease; Cricetinae; Female; Furans; Leishmania donovani; Lei | 1996 |
Efficacy of anticancer alkylphosphocholines in Trypanosoma brucei subspecies.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Drug Synergism; Drug Therap | 1997 |